barsax - I don't think that is a problem at all. Other indications have been talked about on this board for years. Certainly, there have been comments about ABL and other indications at the company AGM's for years. It is likely that if BoM2 is successful that there will be multiple studies started soon afterwards to expand the potential market. 

In the USA alone roughly 10% of the population has lower functioning kidneys. 35ish million potential patients in the USA alone just on the CKD side! Diabetes is another massive market as just over 10% of the population of China is diabetic and that number continues to increase. NASH is yet another massive Potential market.

If this potential partnership works out like they think it will, the $8 billion average for companies with BTD may well be on the low side of the equation that we could potentially be looking at.

This is brand new science that needs to be proven before the value will be trusted by the market. The reduction in CHF in BETonMACE for those patients on SGLT2s and ABL was staggering, the effect on NASH was surprising as well. We know from ASSURE that ABL helped facilitate reverse cholesterol transport when it was in combination with Crestor.

Bottom line: It's almost a sure bet that all of the potential indications are included in whatever negotiations that have or are going on at this time. Toinv has put his list of potential indications up on this board on multiple occasions, there was 18 or 19 on the last one that I saw.

All IMO, dyodd

tada